Protocol Ledger

NCT04197986 · Phase III · TERMINATED

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Interventional Phase III clinical trial protocol NCT04197986 sponsored by QED Therapeutics, a BridgeBio company in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-03-11 Enrollment: 39 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04197986
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)39 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04197986
Protocol FieldVerified Registry Value
NCT IdentifierNCT04197986
Consolidated Lead SponsorQED Therapeutics, a BridgeBio company
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment39 participants (ACTUAL)
Registered Start Date2020-03-11
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI